0001376339-20-000073.txt : 20200804 0001376339-20-000073.hdr.sgml : 20200804 20200804172257 ACCESSION NUMBER: 0001376339-20-000073 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20200804 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200804 DATE AS OF CHANGE: 20200804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MIMEDX GROUP, INC. CENTRAL INDEX KEY: 0001376339 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 262792552 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35887 FILM NUMBER: 201074332 BUSINESS ADDRESS: STREET 1: 1775 W OAK COMMONS COURT, NE CITY: MARIETTA STATE: GA ZIP: 30062 BUSINESS PHONE: (770) 651-9100 MAIL ADDRESS: STREET 1: 1775 W OAK COMMONS COURT, NE CITY: MARIETTA STATE: GA ZIP: 30062 FORMER COMPANY: FORMER CONFORMED NAME: Alynx, Co. DATE OF NAME CHANGE: 20060922 8-K 1 document8k2q2020earnin.htm 8-K Document
false0001376339 0001376339 2020-08-04 2020-08-04


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
____________________

FORM 8-K
____________________

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 4, 2020
MIMEDX GROUP, INC.
(Exact name of registrant as specified in charter)
Florida
 
001-35887
 
26-2792552
(State or other jurisdiction
 
(Commission
 
(IRS Employer
of incorporation)
 
File Number)
 
Identification No.)

1775 West Oak Commons Ct., NE, Marietta GA 30062
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (770) 651-9100
____________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
 
Trading Symbol(s)
 
Name of each exchange
on which registered
None
 
n/a
 
n/a

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐













Item 2.02 Results of Operations and Financial Condition

On August 4, 2020, MiMedx Group, Inc. (the “Company”) issued a press release (the “10-Q Press Release”) announcing the filing of its quarterly report on Form 10-Q for the fiscal quarter ended June 30, 2020. The 10-Q Press Release also includes certain information regarding the Company’s financial results for the fiscal quarter ended June 30, 2020.

A copy of the 10-Q Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.


Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
 
Description of Exhibit
 
 
 
99.1
 
Press release dated August 4, 2020.
104
 
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.


SIGNATURES

Pursuant to the requirements of the Exchange Act, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
 
 
 
 
MIMEDX GROUP, INC.
 
 
 
Date: August 4, 2020
By:
/s/ Peter M. Carlson
 
 
Peter M. Carlson
Chief Financial Officer



 EX-99.1 2 exhibit8k2q2020earnings.htm PRESS RELEASE Exhibit



Exhibit 99.1
MiMedx Files Second Quarter 2020 Form 10-Q
Second Quarter Net Sales of $53.6 million
Results Reflects Tight Cost Containment Efforts
Company to Host Shareholder Update Call on August 11, 2020
MARIETTA, Ga., August 4, 2020 -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the filing of its second quarter 2020 Form 10-Q for the period ended June 30, 2020.
Peter M. Carlson, MiMedx Chief Financial Officer, said, “Our second quarter results demonstrate the effectiveness of the Company’s cost containment actions in offsetting the impact of the COVID-19 pandemic on sales. The business is operating efficiently, and we continue to review and refine our efforts to ensure effective product support and service for our customers, and access to our solutions for patients and families. For MiMedx, the filing of our second quarter 2020 Form 10-Q represents the first timely filing by the Company in almost three years.”
Timothy R. Wright, MiMedx Chief Executive Officer, commented, “The progress made throughout the past year demonstrates that we are moving the Company forward. We believe the resources, expertise and leadership we are putting in place are needed to advance our pipeline and realize the Company’s value potential. Importantly, this progress signals a positive shift in company culture – we are mobilizing around the priorities of our employees and customers, guided by what is best for our patients. The recent financing enables us to invest in our portfolio and in-market brands, and our new senior leadership team brings the skills, integrity, and experience to act strategically, differentiate our products, and lead in our category.”
Highlight of Key Metrics
•
Second quarter net sales of $53.6 million, a 20.4% decrease over the second quarter of 2019
•
Net loss of $8.5 million, reflecting $11.4 million of investigation, restatement and other related expenses
•
Adjusted EBITDA1 of $10.2 million, an improvement over 2019 despite lower sales volume

 
Quarter Ended June 30,
 
Year-to-Date June 30,
 
(in thousands)
 
(in thousands)
 
2020
 
2019
 
2020
 
2019
Net sales
$
53,647

 
$
67,437

 
$
115,383

 
$
133,992

Net loss
(8,466
)
 
(17,210
)
 
(13,287
)
 
(30,483
)
EBITDA1
(4,172
)
 
(14,987
)
 
(16,133
)
 
(26,501
)
Adjusted EBITDA1
10,241

 
9,537

 
13,355

 
20,402

Net loss per common share - basic
$
(0.08
)
 
$
(0.16
)
 
$
(0.12
)
 
$
(0.29
)
Net loss per common share - diluted
$
(0.08
)
 
$
(0.16
)
 
$
(0.12
)
 
$
(0.29
)

1.
EBITDA and Adjusted EBITDA are non-GAAP financial measures. See “Reconciliation of GAAP Net Income to EBITDA and Adjusted EBITDA” for a reconciliation of EBITDA and Adjusted EBITDA to Net loss, located in “Selected Unaudited Financial Information” of this release.




Net sales for the quarter ended June 30, 2020 were $53.6 million, primarily recognized on an “as-shipped” basis, a 20.4% decrease compared to net sales for the same period in 2019 of $67.4 million, recognized on a “cash-receipts” basis. Included in the three months ended June 30, 2020, is $1.7 million of cash collected related to sales made prior to the transition in the Company’s revenue recognition methodology. The decrease in net sales, excluding the impact of the cash collected on the remaining contracts, resulted primarily from the COVID-19 pandemic causing cancellations and postponements for many elective procedures across the U.S. Additionally, due to access restrictions imposed across the country, the Company’s direct sales staff were limited in their ability to retain or generate new business. The restrictions affected all product lines, and materially impacted products across multiple sites of service, including hospital out-patient, hospital in-patient and physician office applications. Gross margin in the second quarter of 2020 was 84.7% as compared to 85.5% in the second quarter of 2019.
Selling, General and Administrative (SG&A) expenses for the second quarter of 2020 decreased $13.3 million, or 26.3%, to $37.3 million compared to $50.6 million for the second quarter of 2019. The decrease was driven, in part, by a temporary decrease in salaries, bonuses, and other expenses to mitigate the impact of the COVID-19 pandemic. The total effect of such measures was a decrease of $4.4 million for the three months ended June 30, 2020, compared to the three months ended June 30, 2019. Lower commissions also contributed to the decrease in SG&A. In addition, the Company reported a year-over-year decrease of $4.9 million in legal, consulting, and accounting expenses not covered in investigation, restatement and related expense. Travel restrictions also caused a reduction in travel-related expenses.
Investigation, restatement and related expenses for the second quarter of 2020 were $11.4 million, compared to $21.0 million for the second quarter of 2019. The decrease was primarily the result of $5.0 million in insurance coverage payments received during the three months ended June 30, 2020 related to litigation involving the Company, its directors and officers, along with a reduction in investigation and litigation costs, as the Audit Committee’s investigation concluded in May 2019.
Research and development expenses were $2.3 million for the second quarter of 2020, compared to $2.8 million for the second quarter of 2019. The decrease is primarily related to year-over-year decreases in clinical trial activities driven by a decrease in patient activity brought upon by the COVID-19 pandemic. While expenses are down compared to prior year, the Company expects these costs to increase over time as it invests in additional clinical and scientific research, including internal product development, clinical efficacy and economic data, and pre-clinical research supportive of future growth objectives.
COVID-19 Update
The ongoing COVID-19 pandemic has impacted the Company’s ability to sell products and access various sites of care across the country as patients stay away from hospitals and other medical facilities. This had an adverse effect on our revenues beginning late in the first quarter of 2020 and continuing into April. By mid-May, access restrictions to hospitals and offices of healthcare providers had eased for the Company’s sales force, and significant numbers of patients began to return for treatment, including for elective procedures. On an “as shipped” basis, net sales in April 2020 and May 2020 were down significantly compared to April 2019 and May 2019, respectively, while net sales in June 2020 were in line with net sales in June 2019.
Beginning in early July 2020, additional restrictions that again limit or postpone elective surgical procedures have been put in place in some areas of the country and, in particular, in areas of the country that contribute a larger portion of sales. Future sales will depend on patients’ willingness to visit healthcare providers for care, and the Company’s sales force’s access to healthcare providers. Also, the severity of the COVID-19 pandemic has been uneven across the country, and future waves of the outbreak of COVID-19 may have a greater impact than did the first wave, depending on where infection rates are highest. The Company is not able to estimate COVID-19’s future effect on patient behavior and consequently future demand or the ability of providers to pay for the Company’s products.




Recent Developments
On July 2, 2020, the Company announced the closing of concurrent $150 million private equity and debt financings, consisting of (1) the sale of shares of a newly created Series B Convertible Preferred Stock for an aggregate purchase price of $100 million, with $90 million provided by an affiliate of EW Healthcare Partners and $10 million provided by Hayfin Capital Management LLP (“Hayfin”), and (2) a five-year term loan facility in the aggregate principal amount of $50 million, the full amount of which has been borrowed and funded, and a one-year delayed draw term loan facility in the aggregate principal amount of $25 million, which has not been drawn or funded.
On July 2, 2020, the Company repaid the remaining principal of its outstanding term loan with Blue Torch Finance LLC, the related prepayment premium, and the accrued interest, with a portion of the proceeds from the equity and debt financings described above.
Shareholder Webcast
MiMedx will host a webcast to review its second quarter 2020 results on Tuesday, August 11, 2020, beginning at 8:30 am, Eastern Time. This webcast can be accessed using the following information:
U.S. Investors: 1-877-407-4018
International Investors: 201-689-8471
Conference ID: 13707734

A replay of the webcast will be available for approximately thirty days on the Company’s website at www.mimedx.com following the conclusion of the webcast.
Important Cautionary Statement
This press release contains forward-looking statements. All statements relating to events or results that may occur in the future are forward-looking statements, including, without limitation, statements regarding expected research and development expenses and the anticipated effects of the COVID-19 pandemic. Forward-looking statements generally can be identified by words such as “expect,” “will,” “intend,” “seek,” “target,” “future,” “plan,” “continue,” “potential,” “possible,” “could,” “would,” “may,” “anticipate,” “to be” and similar expressions. These statements are based on numerous assumptions and involve known and unknown risks, uncertainties and other factors that could significantly affect the Company’s operations and may cause the Company’s actual actions, results, financial condition, performance or achievements to differ materially from any future actions, results, financial condition, performance or achievements expressed or implied by any such forward-looking statements. Factors that may cause such a difference include, without limitation, those discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 and the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020.
Unless required by law, the Company does not intend, and undertakes no obligation, to update or publicly release any revision to any forward-looking statements, whether as a result of the receipt of new information, the occurrence of subsequent events, a change in circumstances or otherwise. Each forward-looking statement contained in this release is specifically qualified in its entirety by the aforementioned factors. Readers are advised to carefully read this release in conjunction with the important disclaimers set forth above prior to reaching any conclusions or making any investment decisions and not to place undue reliance on forward-looking statements, which apply only as of the date of this release.
About MiMedx
MiMedx® is an industry leader in advanced wound care and an emerging therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION® process methodology, among




other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied over 1.9 million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.
Contacts:
Hilary Dixon
Investor Relations & Corporate Communications
770.651.9066
investorrelations@mimedx.com




Selected Unaudited Financial Information

MiMedx Group, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(in thousands)
 
 
June 30,
2020
 
December 31,
2019
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
48,189

 
$
69,069

Accounts receivable, net
30,097

 
32,327

Inventory, net
10,565

 
9,104

Prepaid expenses
2,850

 
6,669

Income tax receivable
10,700

 
18

Other current assets
5,191

 
6,058

Total current assets
107,592

 
123,245

Property and equipment, net
10,820

 
12,328

Right of use asset
2,911

 
3,397

Goodwill
19,976

 
19,976

Intangible assets, net
7,386

 
7,777

Other assets
2,227

 
443

Total assets
$
150,912

 
$
167,166

 
 
 
 
LIABILITIES AND STOCKHOLDERS' EQUITY
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
11,946

 
$
8,710

Accrued compensation
20,784

 
21,302

Accrued expenses
25,768

 
32,161

Current portion of long-term debt
3,750

 
3,750

Other current liabilities
1,415

 
1,399

Total current liabilities
63,663

 
67,322

Long-term debt, net
61,472

 
61,906

Other liabilities
2,917

 
3,540

Total liabilities
128,052

 
132,768

Stockholders’ equity
 
 
 
Preferred stock
—

 
—

Common stock
113

 
113

Additional paid-in capital
151,625

 
147,231

Treasury stock
(13,451
)
 
(10,806
)
Accumulated deficit
(115,427
)
 
(102,140
)
Total stockholders' equity
22,860

 
34,398

Total liabilities and stockholders' equity
150,912

 
167,166







MiMedx Group, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2020
 
2019
 
2020
 
2019
Net sales
$
53,647

 
$
67,437

 
$
115,383

 
$
133,992

Cost of sales
8,198

 
9,749

 
18,223

 
17,167

Gross profit
45,449

 
57,688

 
97,160

 
116,825

 
 
 
 
 
 
 
 
Operating expenses:
 
 
 
 
 
 
 
Selling, general and administrative
37,329

 
50,641

 
84,270

 
101,503

Investigation, restatement and related
11,446

 
21,025

 
27,038

 
39,132

Research and development
2,259

 
2,828

 
4,910

 
5,730

Amortization of intangible assets
271

 
267

 
542

 
500

Impairment of intangible assets
—

 
—

 
—

 
446

Operating loss
(5,856
)
 
(17,073
)
 
(19,600
)
 
(30,486
)
 
 
 
 
 
 
 
 
Other income (expense)
 
 
 
 
 
 
 
Interest expense, net
(2,574
)
 
(269
)
 
(4,961
)
 
(58
)
Other (expense) income, net
(9
)
 
174

 
(3
)
 
145

 
 
 
 
 
 
 
 
Loss before income tax provision
(8,439
)
 
(17,168
)
 
(24,564
)
 
(30,399
)
Income tax provision (expense) benefit
(27
)
 
(42
)
 
11,277

 
(84
)
 
 
 
 
 
 
 
 
Net loss
(8,466
)
 
(17,210
)
 
(13,287
)
 
(30,483
)




MiMedx Group, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(in thousands)
 
Six Months Ended June 30,
 
2020
 
2019
Cash flows from operating activities
 
 
 
Net loss
(13,287
)
 
(30,483
)
Adjustments to reconcile net loss to net cash flows used in operating activities
 
 
 
Share-based compensation
7,783

 
6,513

Depreciation
2,928

 
3,340

Amortization of intangible assets
542

 
500

Amortization of deferred financing costs
1,441

 
116

Bad debt expense
234

 
—

Non-cash lease expenses
486

 
492

Reserve for inventory obsolescence
(217
)
 
500

Loss on fixed asset disposal
1

 
313

Impairment of intangible assets
—

 
1,258

Increase (decrease) in cash resulting from changes in:
 
 
 
Accounts receivable
1,996

 
—

Inventory
(1,243
)
 
534

Prepaid expenses
3,819

 
4,125

Income tax receivable
(10,682
)
 
(80
)
Other current assets
821

 
(1,527
)
Accounts payable
3,236

 
(4,072
)
Accrued compensation
(518
)
 
(3,814
)
Accrued expenses
(12,109
)
 
10,975

Other liabilities
(609
)
 
(1,820
)
Net cash flows used in operating activities
(15,378
)
 
(13,130
)
 
 
 
 
Cash flows from investing activities:
 
 
 
Purchases of equipment
(1,421
)
 
(899
)
Principal payments from note receivable
—

 
389

Patent application costs
(151
)
 
(253
)
Net cash flows used in investing activities
(1,572
)
 
(763
)
 
 
 
 
Cash flows from financing activities:
 
 
 
Proceeds from term loan
10,000

 
72,750

Repayment of term loan
(11,875
)
 
—

Deferred financing cost
(23
)
 
(6,045
)
Stock repurchased for tax withholdings on vesting of restricted stock
(2,330
)
 
(1,109
)
Proceeds from exercise of stock options
298

 
108

Net cash flows (used in) provided by financing activities
(3,930
)
 
65,704

 
 
 
 
Net change in cash
(20,880
)
 
51,811

Cash and cash equivalents, beginning of period
69,069

 
45,118

Cash and cash equivalents, end of period
48,189

 
96,929





Reconciliation of GAAP Net Income to EBITDA and Adjusted EBITDA
In addition to our GAAP results, we provide certain non-GAAP metrics including Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) and Adjusted EBITDA. We believe that the presentation of these measures provides important supplemental information to management and investors regarding our performance. These measurements are not a substitute for GAAP measurements. Company management uses these Non-GAAP measurements as aids in monitoring our ongoing financial performance from quarter-to-quarter and year-to-year on a regular basis and for benchmarking against comparable companies. EBITDA is intended to provide a measure of the Company’s operating performance as it eliminates the effects of financing and capital expenditures. EBITDA consists of GAAP net loss excluding: (i) depreciation, (ii) amortization of intangibles, (iii) interest expense and (iv) income tax provision (benefit). Adjusted EBITDA is intended to provide a normalized view of EBITDA and our broader business operations that we expect to experience on an ongoing basis by removing items that may be irregular, one-time, or non-recurring from EBITDA; most significantly those expenses related to the Audit Committee investigation and restatement. This enables us to identify underlying trends in our business that could otherwise be masked by such items. Adjusted EBITDA consists of GAAP net loss excluding: (i) depreciation, (ii) amortization of intangibles, (iii) interest expense, (iv) income tax provision (benefit), (v) costs incurred in connection with the Audit Committee investigation and restatement, (vi) the effect of the Company’s change in revenue recognition pattern, (vii) impairment of intangible assets and (viii) share-based compensation. A reconciliation of GAAP Net Loss to EBITDA and Adjusted EBITDA appears in the table below (in thousands).
 
Three Months Ended June 30,
 
Six Months Ended June 30
 
2020
 
2019
 
2020
 
2019
Net loss
$
(8,466
)
 
$
(17,210
)
 
$
(13,287
)
 
$
(30,483
)
Net margin
(15.80
)%
 
(25.50
)%
 
(11.50
)%
 
(22.70
)%
Non-GAAP Adjustments:
 
 
 
 
 
 
 
Depreciation expense
1,422

 
1,645

 
2,928

 
3,340

Amortization of intangible assets
271

 
267

 
542

 
500

Interest expense, net
2,574

 
269

 
4,961

 
58

Income tax provision expense (benefit)
27

 
42

 
(11,277
)
 
84

EBITDA
$
(4,172
)
 
$
(14,987
)
 
$
(16,133
)
 
$
(26,501
)
EBITDA margin
(7.80
)%
 
(22.20
)%
 
(14.00
)%
 
(19.80
)%
Additional Non-GAAP Adjustments
 
 
 
 
 
 
 
Costs incurred in connection with the Audit Committee investigation and restatement
11,446

 
21,025

 
27,038

 
39,132

Effect of change in revenue recognition
(1,467
)
 
—

 
(5,333
)
 
—

Impairment of intangible assets
—

 
—

 
—

 
1,258

Share-based compensation
4,314

 
3,499

 
7,783

 
6,513

Adjusted EBITDA
$
10,121

 
$
9,537

 
$
13,355

 
$
20,402

Adjusted EBITDA margin
19.1
 %
 
14.1
 %
 
11.6
 %
 
15.2
 %



 EX-101.SCH 3 mdxg-20200804.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0004000 - Document - Cover Page Document link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 mdxg-20200804_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 mdxg-20200804_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 mdxg-20200804_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag EX-101.PRE 7 mdxg-20200804_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 document8k2q2020earnin_htm.xml IDEA: XBRL DOCUMENT 0001376339 2020-08-04 2020-08-04 false 0001376339 8-K 2020-08-04 MIMEDX GROUP, INC. FL 001-35887 26-2792552 1775 West Oak Commons Ct., NE Marietta GA 30062 770 651-9100 false false false false false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover Page Document
Aug. 04, 2020
Cover [Abstract]  
Document Type 8-K
Document Period End Date Aug. 04, 2020
Entity Registrant Name MIMEDX GROUP, INC.
Entity Incorporation, State or Country Code FL
Entity File Number 001-35887
Entity Tax Identification Number 26-2792552
Entity Address, Address Line One 1775 West Oak Commons Ct., NE
Entity Address, City or Town Marietta
Entity Address, State or Province GA
Entity Address, Postal Zip Code 30062
City Area Code 770
Local Phone Number 651-9100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0001376339
Amendment Flag false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 0 false false R1.htm 0004000 - Document - Cover Page Document Sheet http://mimedx.com/role/CoverPageDocument Cover Page Document Cover 1 false false All Reports Book All Reports document8k2q2020earnin.htm exhibit8k2q2020earnings.htm mdxg-20200804.xsd mdxg-20200804_cal.xml mdxg-20200804_def.xml mdxg-20200804_lab.xml mdxg-20200804_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true true JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "document8k2q2020earnin.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "mdxg-20200804_cal.xml" ] }, "definitionLink": { "local": [ "mdxg-20200804_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "document8k2q2020earnin.htm" ] }, "labelLink": { "local": [ "mdxg-20200804_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "mdxg-20200804_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "mdxg-20200804.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 20, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mdxg", "nsuri": "http://mimedx.com/20200804", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "document8k2q2020earnin.htm", "contextRef": "D2020Q2", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0004000 - Document - Cover Page Document", "role": "http://mimedx.com/role/CoverPageDocument", "shortName": "Cover Page Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "document8k2q2020earnin.htm", "contextRef": "D2020Q2", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r3": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r4": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001376339-20-000073-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001376339-20-000073-xbrl.zip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end